Device Trial Radar · NCT07858994
Effects of Fractional CO2 Vaginal Laser in Postmenopausal Women With Genitourinary Syndrome of Menopause
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Nov 9, 2023
Primary completion
Jul 31, 2025
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- Karina Amar SvecAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Female only, from 45 years, up to 68 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the effects of fractional carbon dioxide (CO2) vaginal laser treatment in postmenopausal women with genitourinary syndrome of menopause. Ten women underwent three fractional CO2 laser sessions at 30 to 40-day intervals. Clinical and vaginal assessments were performed before treatment and during follow-up. Vaginal tissue samples were collected at baseline, approximately one month after completion of treatment, and at long-term follow-up to evaluate histological changes, including collagen, vascularization, and estrogen receptor expression. Participants were followed through the long-term assessment performed approximately one year or more after treatment.
Conditions
- Genitourinary Syndrome of Menopause (GSM)
Interventions
Fractional CO2 Vaginal LaserDevice
Fractional microablative CO2 vaginal laser treatment was performed using the MTZ40 device with a 360-degree intravaginal probe. Treatment parameters were 28 W, pulse duration of 6.5 ms, and 45 DOTS. Participants received three treatment sessions at 30- to 40-day intervals. During each session, a single pass was performed along the vaginal walls, starting at the vaginal fornix and withdrawing the probe distally in 0.5-cm increments.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Estrogen Receptor Alpha (ERα) Expression in Vaginal MucosaTime frame: Baseline, 30 days after the third laser session, and long-term follow-up (median 17 months after the third laser session)
- Microvascular Density Assessed by CD34 ImmunostainingTime frame: Baseline, 30 days after the third laser session, and long-term follow-up (median 17 months after the third laser session)
- Collagen Deposition in Vaginal MucosaTime frame: Baseline, 30 days after the third laser session, and long-term follow-up (median 17 months after the third laser session)
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Irmandade da Santa Casa de Misericórdia de São Paulo
São Paulo, São Paulo, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.